Among all growth funds, health-care investments have increased 14 percent over the last three years, to make up 16 percent of portfolios.» Read More
The heightened rhetoric comes as Chicago tries to recover millions in health care costs from opioid drugmakers, alleging that companies deliberately misled the public about the risks of their drugs.
*Expects key drug launches in fourth quarter despite FDA delay. Aug 7- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories, Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.
*Cuts top end of FY earnings forecast to $3.45/ shr from $3.60/ shr. Aug 7- Mylan Inc shaved the top end of its full-year revenue and earnings forecasts, citing delays in approval from the U.S. Food and Drug Administration for key generic drugs that it plans to launch this year.
*Q2 EPS ex-items $1.23 vs $1.22 forecast. *Now sees 2014 EPS $4.50- $4.80 with Copaxone competition. TEL AVIV, July 31- Teva Pharmaceutical Industries raised its full-year profit forecast on Thursday after posting higher quarterly earnings that were due in part to the launch of several generic products in the United States.
JERUSALEM, July 31- Israeli industrialist Benny Landa said his campaign to improve corporate governance at Teva Pharmaceutical Industries was delivering results, despite losing a shareholder vote at the world's largest generic drugmaker.
However, the report from the Generic Pharmaceutical Association said REMS have been used to prevent generic drugmakers from getting branded medicine to test their own versions, which is required to win FDA approval.
U.S. sales of $585 million far exceeded Wall Street forecasts in the $485 million range. The drug is taking flight as patients with the progressive neurological disease move from injectable treatments to more convenient pills, including Novartis AG's Gilenya and Sanofi SA's Aubagio.
Allergan told its stockholders not to respond to Pershing Square Capital Management's proposal to replace a majority of the board.
TEL AVIV, July 3- Teva Pharmaceutical Industries has filed a so-called citizen petition with the U.S. Food and Drug Administration, aiming to delay cheap generic competition to Copaxone, its top-selling treatment for multiple sclerosis.
A three-judge panel of the 6th U.S. Circuit Court of Appeals in Cincinnati rejected claims in 67 of the cases. Among the defendants in the various cases were Eli Lilly& Co, which won regulatory approval for Darvon in 1957 and Darvocet in 1972, and generic drug makers such as Mylan Inc and Teva Pharmaceutical Industries Ltd..
*European Commission declines to comment. BRUSSELS, June 19- EU antitrust regulators are set to fine French drugmaker Servier, Israel's Teva and several of their peers next month for blocking cheaper generic medicine, two people with knowledge of the matter said on Thursday.
A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.
Take a look at some of Tuesday's midday movers:
Chicago filed a lawsuit against five pharmaceutical companies, accusing them of concealing the risks associated with certain painkillers.
Some of Wednesday's midday movers:
Take a look at some of Thursday's midday movers:
The case, in U.S. District Court in Washington, D.C., was dismissed on Wednesday as being premature because the FDA had not yet approved or rejected the applications for generic forms of the drug, Teva said.
May 15- Mylan Inc said a U.S. district court dismissed a case by Israeli drugmaker Teva Pharmaceutical Industries Ltd intended to block the U.S. health regulator from approving generic versions of Teva's multiple sclerosis drug Copaxone. U.S. generic drugmaker Mylan said it had intervened in the lawsuit in support of the U.S. Food and Drug Administration.
As rivals assessed what Pfizer's play for AstraZeneca could mean for the industry, one aspect touched nearly everyone: What it could mean for a U.S. tax loophole.
Stocks closed out April with a bang and many watchers believe this is not the year to sell in May.